Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939312 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 685
- Enrollment target
NCT03939312 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 685 participants.
The verdict
NCT03939312, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 685 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Interventions
- DRUG Atogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2019-05-06 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939312
The ClinicalTrials.gov registry entry for NCT03939312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 685 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atogepant is the first listed.
NCT03939312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03939312 about?
NCT03939312 is a clinical study titled "Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine". The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
What is the current status of trial NCT03939312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 685 participants. The study started on 2019-05-06. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03939312?
The interventions under investigation include: Atogepant (DRUG).
Who is sponsoring clinical trial NCT03939312?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.